Monte Rosa Therapeutics, Inc. GLUE Stock Forecast
AI-powered price prediction and analysis for Monte Rosa Therapeutics, Inc. · Alpha · vs marketSwitch to Total
See GLUE's Exact Price Target · Create a free account and follow this stock to unlock its full AI forecast — 3 stocks free.
Price Chart
Key Statistics
About Monte Rosa Therapeutics, Inc.
Monte Rosa Therapeutics, Inc. (GLUE) operates within the Life Sciences sector, specifically in the Biological Products, (No Diagnostic Substances) industry.
Latest News
- Monte Rosa Therapeutics, Inc.: Monte Rosa Therapeutics Announces Positive Results for MRT-8102 in GFORCE-1 Phase 1 Study Showing Normalization of Key Pathogenic Drivers of ...
- Monte Rosa Therapeutics to Present Results of MRT-8102 GFORCE-1 Phase 1 Study in Subjects with Elevated Cardiovascular Disease Risk
- GLUE stock soars over 20% pre-market: What's driving the surge?
- Sign up free to read all 12 articles →
Where GLUE sits on the market map
Biological Products, (No Diagnostic Substances) Peers
Companies sharing the same SEC industry code, one row per issuer, largest first - a classification match, not a curated list of competitors.
| Company | AI Signal | Market Cap | P/E |
|---|---|---|---|
| GLUE Monte Rosa Therapeutics, Inc. | ▲ | $844M | – |
| AMGN Amgen Inc | ▼ | $223.19B | 25.5x |
| GILD Gilead Sciences, Inc. | ▶ | $183.41B | – |
| MRNA Moderna, Inc. | ▲ | $86.33B | – |
| ARGX Argenx Se | ▶ | $49.67B | – |
| RVMD Revolution Medicines, Inc. | ▲ | $40.39B | – |
| BIIB Biogen Inc. | ▼ | $33.79B | 23.6x |
| BNTX Biontech Se | ▶ | $22.51B | – |
| MESO Mesoblast Ltd | ▼ | $18.02B | – |
| EXEL Exelixis, Inc. | ▲ | $14.75B | – |
| NBIX Neurocrine Biosciences Inc | ▼ | $13.74B | 19.5x |
| HALO Halozyme Therapeutics, Inc. | ▲ | $12.44B | 30.1x |
| TECH Bio-Techne Corp | ▼ | $11.37B | 62.5x |
| IBRX Immunitybio, Inc. | ▲ | $10.39B | – |
| PCVX Vaxcyte, Inc. | ▲ | $9.94B | – |
| RGEN Repligen Corp | ▲ | $9.90B | 238.3x |
| QGEN Qiagen N.V. | ▼ | $9.86B | – |
| KRYS Krystal Biotech, Inc. | ▲ | $9.51B | 39.4x |
| TWST Twist Bioscience Corp | ▲ | $9.49B | – |
| KYMR Kymera Therapeutics, Inc. | ▲ | $8.87B | – |
| IOVA Iovance Biotherapeutics, Inc. | ▲ | $6.57B | – |
| IMVT Immunovant, Inc. | ▲ | $5.93B | – |
| KOD Kodiak Sciences Inc. | ▲ | $5.76B | – |
| CGON Cg Oncology, Inc. | ▲ | $5.53B | – |
| SRRK Scholar Rock Holding Corp | ▲ | $4.93B | – |
| CRSP Crispr Therapeutics Ag | ▲ | $4.84B | – |
| ADPT Adaptive Biotechnologies Corp | ▲ | $4.03B | – |
| RLAY Relay Therapeutics, Inc. | ▲ | $3.80B | – |
| TARS Tarsus Pharmaceuticals, Inc. | ▲ | $3.11B | – |
| DNLI Denali Therapeutics Inc. | ▲ | $2.94B | – |
| DBVT Dbv Technologies S.A. | ▼ | $2.67B | – |
| BEAM Beam Therapeutics Inc. | ▲ | $2.52B | – |
| ADMA Adma Biologics, Inc. | ▲ | $2.31B | 13.7x |
| NVAX Novavax Inc | ▲ | $2.11B | – |
| VCEL Vericel Corp | ▶ | $2.06B | 85.2x |
| BCRX Biocryst Pharmaceuticals Inc | ▲ | $2.06B | – |
| RXRX Recursion Pharmaceuticals, Inc. | ▲ | $2.05B | – |
| VIR Vir Biotechnology, Inc. | ▲ | $1.80B | – |
| SCNI Scinai Immunotherapeutics Ltd. | ▶ | $1.71B | – |
| ALVO Alvotech | ▶ | $1.68B | – |
| MAZE Maze Therapeutics, Inc. | ▲ | $1.48B | – |
| IMCR Immunocore Holdings Plc | ▲ | $1.43B | – |
| COAG Hemab Therapeutics Holdings, Inc. | ▲ | $1.39B | – |
| TSHA Taysha Gene Therapies, Inc. | ▲ | $1.17B | – |
| REPL Replimune Group, Inc. | ▲ | $1.14B | – |
| VOR Vor Biopharma Inc. | ▶ | $1.13B | – |
| JATT Zura Bio Ltd | ▼ | $1000M | – |
| VALN Valneva Se | ▼ | $965M | – |
| MGTX Meiragtx Holdings Plc | ▶ | $955M | 12.1x |
| IMTX Immatics N.V. | ▶ | $916M | – |
| CGEM Cullinan Therapeutics, Inc. | ▲ | $907M | – |
| ODTX Odyssey Therapeutics, Inc. | ▲ | $829M | – |
| DNA Ginkgo Bioworks Holdings, Inc. | ▲ | $792M | – |
| SANA Sana Biotechnology, Inc. | ▶ | $721M | – |
| CADL Candel Therapeutics, Inc. | ▲ | $709M | – |
| FDMT 4d Molecular Therapeutics, Inc. | ▲ | $682M | – |
| AURA Aura Biosciences, Inc. | ▲ | $650M | – |
| SLDB Solid Biosciences Inc. | ▲ | $624M | – |
| PRME Prime Medicine, Inc. | ▲ | $602M | – |
| RGNX Regenxbio Inc. | ▲ | $479M | – |
FAQ
Is Monte Rosa Therapeutics, Inc. a good stock to buy?
Our AI analyzes Monte Rosa Therapeutics, Inc. daily. Check the signal above for the latest recommendation. Always do your own research before investing.
How accurate are Monte Rosa Therapeutics, Inc. predictions?
A per-ticker accuracy statistic for GLUE is published only once its sample size is known. Across our coverage, the out-of-sample test on 4537 stocks from 2025-01-06 to 2026-06-09 produced a positive net return in 73.7% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
How often are forecasts updated?
Monte Rosa Therapeutics, Inc. forecasts are refreshed on trading days as the daily model run completes. The forecast on this page was produced on Oct. 14, 2026.
Ready to invest smarter? · Join thousands of investors using AI-powered stock predictions
Sign Up FreeLooking for a deeper analysis of Monte Rosa Therapeutics, Inc.? View full institutional-grade analysis on Intratio →
AI predictions are based on historical patterns and should not be the sole basis for investment decisions. Past performance does not guarantee future results. Always do your own research.